Abstract
The incidence of leptomeningeal metastases (LM) is approximately 9% in epidermal growth factor receptor-mutated (EGFRm) NSCLC with extremely poor prognosis. Aumolertinib (formerly almonertinib; HS-10296) is a novel 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The preclinical evidence in nonhuman primates shows that aumolertinib has high penetration of the blood-brain barrier and brain exposure compared with other EGFR-TKI. In this study, we researched the efficacy of aumolertinib monotherapy or combination therapy with EGFR-mutated NSCLC leptomeningeal metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
